Short answer
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed its Q3 2026 10-Q quarterly report on Oct 23, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $411M (up 2.3% year over year) with net income of $15M.
Q3 2026 key financials · XBRL
- Revenue
- $411M
- +2.3% YoY · −1.8% QoQ
- Net income
- $15M
- +374.8% YoY · +231.3% QoQ
- Operating margin
- 4.6%
- EPS (diluted)
- $0.19
- +371.4% YoY · +216.7% QoQ
Source: XBRL data from the INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Q3 2026 10-Q on SEC EDGAR. USD.
INTEGRA LIFESCIENCES HOLDINGS CORP Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $411.2M, up $9.1M YoY from $402.1M, low-single-digit growth
- Specialty Surgery $304.1M, up 4% YoY; Tissue Reconstruction $107.1M, down 2%
- Gross margin 51.0% vs 51.5% YoY; operating expenses 46.4% vs 48.5%
- Cash $252.3M vs $235.0M at December 31, 2025; nine-month operating cash flow $128.6M vs $38.6M
- Cincinnati disruption reduced revenue approximately $7M; facility recovery expected during second quarter 2027, SurgiMend relaunch targeted fourth quarter 2026
Risk Factors
- No material changes to risk factors from the December 31, 2025 Form 10-K
- Carried-forward risks remain governed by the previously filed annual report
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other INTEGRA LIFESCIENCES HOLDINGS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.